Fig. 9
From: Methylation across the central dogma in health and diseases: new therapeutic strategies

Paradigm of site-specific manipulating chromatin methylation for precise cancer therapy. mRNAs encoding a methylation editor are delivered to liver cancer cells by lipid nanoparticles (LNPs), which suppresses oncogene expression by catalyzing DNA and/or histone methylation at the promoters of oncogenes (e.g., MYC) or at the CTCF-binding sites to abolish their interactions with potential enhancers